Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601259 | 1.00 | LCK (0.53) | LCKPTPN11CA1CA2CA12 | |
| SCHEMBL1779743 | 1.00 | LCK (0.53) | LCKPTPN11CA1CA2CA12 | |
| SCHEMBL18704258 | 0.84 | CA1 (0.53) | CA1CA2CA12CA7XDH | |
| SCHEMBL29365729 | 0.82 | PTPN11 (0.68) | LCKPTPN11CA1CA2CA12 | |
| SCHEMBL69025 | 0.82 | PTPN11 (0.68) | LCKPTPN11CA1CA2CA12 | |
| SCHEMBL31148953 | 0.81 | MAPT (0.56) | LCKPTPN11CA1CA2CA12 | |
| SCHEMBL31148952 | 0.81 | MAPT (0.56) | LCKPTPN11CA1CA2CA12 | |
| SCHEMBL8732524 | 0.80 | PTPN11 (0.66) | LCKPTPN11CA1CA2CA12 | |
| SCHEMBL13709384 | 0.79 | KDM4E (0.45) | CA1CA2CA12CA7XDH | |
| SCHEMBL22562933 | 0.79 | CA12 (0.57) | LCKCA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943795-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY | 2009-09-17 | — | — | US | disclosed |
| EP-1836151-B1 | VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-04-01 | — | — | EP | disclosed |
| EP-1836151-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006069153-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234001-A1 | VITAMIN D RECEPTOR MODULATORS | VDR, CYP2R1, CYP24A1 | LCK 4617/4885PTPN11 939/4885CA1 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.